Vol 92, No 1 (2021)
Clinical vignette
Published online: 2021-01-25

open access

Page views 829
Article views/downloads 838
Get Citation

Connect on Social Media

Connect on Social Media

Successful perinatal management and pacemaker stimulation during the first hour of life in a 1.6 kg newborn with autoimmune congenital complete heart block diagnosed prenatally

Anna Wojtowicz1, Tomasz Mroczek2, Janusz Skalski2, Hubert Huras1, Agata Wloch3
Pubmed: 33576493
Ginekol Pol 2021;92(1):80-81.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Bordachar P, Zachary W, Ploux S, et al. Pathophysiology, clinical course, and management of congenital complete atrioventricular block. Heart Rhythm. 2013; 10(5): 760–766.
  2. Wainwright B, Bhan R, Trad C, et al. Autoimmune-mediated congenital heart block. Best Pract Res Clin Obstet Gynaecol. 2020; 64: 41–51.
  3. Skog A, Lagnefeldt L, Conner P, et al. Outcome in 212 anti-Ro/SSA-positive pregnancies and population-based incidence of congenital heart block. Acta Obstet Gynecol Scand. 2016; 95(1): 98–105.
  4. Buyon JP, Hiebert R, Copel J, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol. 1998; 31(7): 1658–1666.
  5. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation. 2012; 126(1): 76–82.
  6. Glatz AC, Gaynor JW, Rhodes LA, et al. Outcome of high-risk neonates with congenital complete heart block paced in the first 24 hours after birth. J Thorac Cardiovasc Surg. 2008; 136(3): 767–773.
  7. Julkunen H, Eronen M. The rate of recurrence of isolated congenital heart block: a population-based study. Arthritis Rheum. 2001; 44(2): 487–488, doi: 10.1002/1529-0131(200102)44:2<487::AID-ANR70>3.0.CO;2-D.
  8. Brito-Zerón P, Izmirly PM, Ramos-Casals M, et al. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol. 2015; 11(5): 301–312.
  9. Costedoat-Chalumeau N, Georgin-Lavialle S, Amoura Z, et al. Anti-SSA/Ro and anti-SSB/La antibody-mediated congenital heart block. Lupus. 2005; 14(9): 660–664.
  10. Jaeggi ET, Hamilton RM, Silverman ED, et al. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30 years. J Am Coll Cardiol. 2002; 39(1): 130–137.
  11. Michaëlsson M, Jonzon A, Riesenfeld T. Isolated congenital complete atrioventricular block in adult life. A prospective study. Circulation. 1995; 92(3): 442–449.
  12. Buyon JP, Hiebert R, Copel J, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol. 1998; 31(7): 1658–1666.
  13. Jaeggi ET, Hamilton RM, Silverman ED, et al. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30 years. J Am Coll Cardiol. 2002; 39(1): 130–137.
  14. Von Sc, Fink C, Peuster M, et al. Permanent pacemaker implantation in a 1445 g preterm neonate on the first day of life. J Thorac Cardiovasc Surg. 2002; 50: 360–366.
  15. Donofrio MT, Gullquist SD, Mehta ID, et al. Congenital complete heart block: fetal management protocol, review of the literature, and report of the smallest successful pacemaker implantation. J Perinatol. 2004; 24(2): 112–117.
  16. Maeno Y, Himeno W, Saito A, et al. Clinical course of fetal congenital atrioventricular block in the Japanese population: a multicentre experience. Heart. 2005; 91(8): 1075–1079.